196 related articles for article (PubMed ID: 37093312)
21. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
[TBL] [Abstract][Full Text] [Related]
22. [
Wei Y; Zheng J; Ma L; Liu X; Xu S; Wang S; Pei J; Cheng K; Yuan S; Yu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2761-2773. PubMed ID: 35262766
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation and pilot clinical study of [
Ge L; Fu Z; Wei Y; Shi D; Geng Y; Fan H; Zhang R; Zhang Y; Li S; Wang S; Shi H; Song G; Pan J; Cheng K; Wang L
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4025-4036. PubMed ID: 35715613
[TBL] [Abstract][Full Text] [Related]
24. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
25. A comparison of [
Liu N; Wan Q; Wu X; Zhao T; Jakobsson V; Yuan H; Chen X; Zhang J; Zhang W
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1685-1697. PubMed ID: 38246909
[TBL] [Abstract][Full Text] [Related]
26. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of a novel stable peptide PET molecular probe [
Yao B; Wang L; Xie C; Li M; Peng C; Li Z; Lu W; Chen J
Nucl Med Biol; 2023; 118-119():108330. PubMed ID: 36889247
[TBL] [Abstract][Full Text] [Related]
29. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
31. Preparation and Evaluation of [
Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411
[TBL] [Abstract][Full Text] [Related]
32. [
Wei Y; Cheng K; Fu Z; Zheng J; Mu Z; Zhao C; Liu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1671-1681. PubMed ID: 34870727
[TBL] [Abstract][Full Text] [Related]
33. A preliminary clinical trial to evaluate
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
[TBL] [Abstract][Full Text] [Related]
35. [Tumor targeting efficacy of a novel PET radiotracer (1)8F-AlF-NOTA-PRGD2 in mice].
Wu H; Wang Q; Han Y; Zhou W; Li H; Tian Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):51-5. PubMed ID: 24463116
[TBL] [Abstract][Full Text] [Related]
36. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2.
Gao H; Lang L; Guo N; Cao F; Quan Q; Hu S; Kiesewetter DO; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):683-92. PubMed ID: 22274731
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model.
Guo N; Lang L; Li W; Kiesewetter DO; Gao H; Niu G; Xie Q; Chen X
PLoS One; 2012; 7(5):e37506. PubMed ID: 22624041
[TBL] [Abstract][Full Text] [Related]
38. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
39. FAPI-74 PET/CT Using Either
Giesel FL; Adeberg S; Syed M; Lindner T; Jiménez-Franco LD; Mavriopoulou E; Staudinger F; Tonndorf-Martini E; Regnery S; Rieken S; El Shafie R; Röhrich M; Flechsig P; Kluge A; Altmann A; Debus J; Haberkorn U; Kratochwil C
J Nucl Med; 2021 Feb; 62(2):201-207. PubMed ID: 32591493
[No Abstract] [Full Text] [Related]
40. Syntheses and Preliminary Evaluation of Dual Target PET Probe [18F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer.
Chen Z; Fu H; Wu H; Huang J; Yao L; Zhang X; Li Y
Anticancer Agents Med Chem; 2020; 20(13):1548-1557. PubMed ID: 32329699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
